Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that Mary Rozenman, Ph.D., Senior Vice President of Corporate Development and Strategy at Aimmune, will present a company overview at Cantor Fitzgerald’s 2nd Annual Healthcare Conference in New York City, on Tuesday, July 12, 2016, at 3:30 p.m. Eastern Time.
The live webcast of the presentation will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. The replay of the webcast will be available for 14 days following the webcast.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) system, an approach to oral immunotherapy (OIT), uses rigorously characterized product candidates with gradual, controlled up-dosing protocols to obtain clinically meaningful desensitization to food allergens. Aimmune’s first CODIT product, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age. Aimmune’s Phase 3 trial of AR101, PALISADE, is now enrolling patients. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160705005387/en/
Contacts:
Investors
Laura Hansen, Ph.D.,
650-396-3814
lhansen@aimmune.com
or
Media
Stephanie
Yao, 650-351-6479
Psyao@aimmune.com